Comparative Pharmacology
Head-to-head clinical analysis: FANSIDAR versus SOVUNA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FANSIDAR versus SOVUNA.
FANSIDAR vs SOVUNA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Fansidar combines sulfadoxine, a sulfonamide dihydrofolate reductase inhibitor, and pyrimethamine, a dihydrofolate reductase inhibitor, synergistically inhibiting folate synthesis in Plasmodium species, leading to nucleic acid synthesis inhibition and parasite death.
SOVUNA (suvorexant) is a dual orexin receptor antagonist that blocks the binding of orexin neuropeptides to orexin OX1 and OX2 receptors, thereby promoting sleep initiation and maintenance.
For acute uncomplicated malaria: 3 tablets (25 mg pyrimethamine + 500 mg sulfadoxine per tablet) orally as a single dose on Day 0 and Day 1 (total 6 tablets); alternatively, 3 tablets as a single dose. For severe malaria: 3 tablets orally as a single dose, repeated at weekly intervals if necessary.
400 mg orally once daily with food.
None Documented
None Documented
Sulfadoxine: 100-200 hours; pyrimethamine: 80-100 hours; clinical context: unusual for antimalarials, allows single-dose therapy for uncomplicated P. falciparum
Terminal half-life 14 hours; clinically significant for once-daily dosing, requiring dose adjustment in renal impairment (CrCl <30 mL/min).
Renal: sulfadoxine 80% (unchanged), pyrimethamine 20-40% (unchanged); fecal: sulfadoxine <5%, pyrimethamine <5%
Primarily renal (70% unchanged) and 20% fecal via bile; minor metabolic clearance.
Category C
Category C
Antimalarial
Antimalarial